-+ 0.00%
-+ 0.00%
-+ 0.00%

Jincheng Pharmaceutical announced that the company's wholly-owned subsidiary Jincheng Taier's didrogesterone tablets and the holding subsidiary Jincheng Jinsu's injectable etapenem sodium will be selected for centralized procurement of the 12th batch of national drugs. The proposed prices are 25.5 yuan/box and 44.5 yuan/box, respectively. Didroprogesterone tablets were approved in April 2026 and have not been sold until now; sales revenue of injectable ertapenem sodium in 2025 was 487,800 yuan. The procurement period starts on the date of execution of the selected results and ends on December 31, 2029.

Zhitongcaijing·08/03/2026 09:01:04
Listen to the news
Jincheng Pharmaceutical announced that the company's wholly-owned subsidiary Jincheng Taier's didrogesterone tablets and the holding subsidiary Jincheng Jinsu's injectable etapenem sodium will be selected for centralized procurement of the 12th batch of national drugs. The proposed prices are 25.5 yuan/box and 44.5 yuan/box, respectively. Didroprogesterone tablets were approved in April 2026 and have not been sold until now; sales revenue of injectable ertapenem sodium in 2025 was 487,800 yuan. The procurement period starts on the date of execution of the selected results and ends on December 31, 2029.